Szylling Anna, Samoliński Boleslaw, Raciborski Filip, Furmańczyk Konrad, Chrzanowska Mariola, Wojas Oksana, Krzych-Fałta Edyta, Gawińska-Drużba Emilia, Samoliński Krzysztof, Bousquet Jean, Samel-Kowalik Piotr
Department of Allergy and Clinical Immunology, University Clinical Center of the Medical University of Warsaw Central Clinical Hospital, Warszawa, Mazowieckie, Poland.
Department of Prevention of Environmental Hazards, Medical University of Warsaw, Warszawa, Mazowieckie, Poland.
Clin Transl Allergy. 2025 Apr;15(4):e70054. doi: 10.1002/clt2.70054.
Monitoring adherence in chronic diseases remains a significant challenge. Allergic rhinitis (AR), one of the most common chronic conditions, serves as an excellent model for studying determinants of app use in monitoring adherence and health assessment during treatment. The Mask-air® app supports clinical decision-making by involving patients in symptom observation and promoting adherence to therapy. This study aimed to identify the defining characteristics of Mask-air® users, describe their disease phenotype and satisfaction with the app, and explore reasons for discontinuation.
Adult patients 20-44 years old suffering from AR (n = 198) receiving care at an allergy outpatient clinic were invited to participate in a trial using the Mask-air® app. Investigators collected data on symptoms, administered treatments, and clinical evaluation results through questionnaires. At a follow-up visit (n = 163), these were compared, and patients were questioned about their satisfaction with the app. Patients presented their app records, and those who declined or stopped using the app were asked to provide reasons in a questionnaire.
No distinguishing characteristics of Mask-air® users (n = 131) were identified compared with those who declined the app (n = 67). App readiness was analyzed according to age, socioeconomic status, disease severity, comorbidities, and therapeutic modality. Respondents were categorized into: those who did not install the app (17.7%), those who installed but did not use it (16.2%), and those who installed and evaluated it (66.2%), with 15.6% failing to produce symptom monitoring records. Overall, satisfaction ratings were high though patients were critical of the app's therapeutic aspect.
The study found no specific features distinguishing Mask-air® users, suggesting that it can be recommended to all patients regardless of gender, socioeconomic or educational status, or disease phenotype. However, with a dropout rate of nearly 50%, it is essential for clinicians to emphasize the app's benefits to improve adherence and engagement.
监测慢性病患者的依从性仍然是一项重大挑战。过敏性鼻炎（AR）是最常见的慢性病之一，是研究应用程序在治疗期间监测依从性和健康评估中使用的决定因素的理想模型。Mask-air®应用程序通过让患者参与症状观察并促进治疗依从性来支持临床决策。本研究旨在确定Mask-air®用户的特征，描述他们的疾病表型和对该应用程序的满意度，并探讨停用的原因。
邀请在过敏门诊接受治疗的20-44岁成年AR患者（n = 198）参与使用Mask-air®应用程序的试验。研究人员通过问卷调查收集有关症状、所接受治疗和临床评估结果的数据。在随访时（n = 163），对这些数据进行比较，并询问患者对该应用程序的满意度。患者展示他们的应用程序记录，那些拒绝或停止使用该应用程序的患者被要求在问卷中提供原因。
与拒绝使用该应用程序的患者（n = 67）相比，未发现Mask-air®用户（n = 131）有明显特征。根据年龄、社会经济地位、疾病严重程度、合并症和治疗方式对应用程序的准备情况进行了分析。受访者分为：未安装该应用程序的患者（17.7%）、安装但未使用的患者（16.2%）以及安装并进行评估的患者（66.2%），有15.6%的患者未能生成症状监测记录。总体而言，尽管患者对该应用程序的治疗方面提出了批评，但满意度评分较高。
该研究未发现区分Mask-air®用户的特定特征，这表明无论性别、社会经济或教育状况或疾病表型如何，均可向所有患者推荐该应用程序。然而，由于退出率近50%，临床医生必须强调该应用程序的益处，以提高依从性和参与度。
